IP Library › Granted Patent US 8,173,126
Granted Patent B2
US 8,173,126 · App. 11/812,296 · Granted May 8, 2012

Blood VEGF level-lowering agent containing IL-6 antagonist as the active ingredient

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,173,126
App. No.
11/812,296
Granted
May 8, 2012
Kind
B2
Abstract

A blood vascular endothelial growth factor (VEGF) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Claims (19)

1. A method for lowering blood VEGF level, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman's Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to lower blood VEGF level.

2. The method according to claim 1 , wherein the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

3. The method according to claim 1 , in which the antibody against IL-6 receptor is a recombinant antibody.

4. The method according to claim 1 , in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

5. The method of claim 1 , wherein the blood VEGF level is lowered to at least 500 pg/ml.

6. A method for lowering blood VEGF level, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman's Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to lower blood VEGF level, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

7. The method according to claim 6 , in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

8. A method for lowering blood VEGF level, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman's Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to lower blood VEGF level, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

9. The method according to claim 8 , in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

10. A method for lowering blood VEGF level, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman's Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to lower blood VEGF level, in which the antibody against IL-6 receptor is a humanized PM-1 antibody.

11. A method for inhibiting angiogenesis, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman's Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to inhibit angiogenesis.

12. The method according to claim 11 , in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

13. The method according to claim 12 , in which the monoclonal antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

14. The method according to claim 13 , in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

15. The method according to claim 12 , in which the monoclonal antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

16. The method according to claim 15 , in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

17. The method according to claim 11 , in which the antibody against IL-6 receptor is a recombinant antibody.

18. The method according to claim 11 , in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

19. The method according to claim 18 , in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.